Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities

Stoll, 2004, Potential role of endotoxin as a proinflammatory mediator of atherosclerosis, Arterioscler Thromb Vasc Biol, 24, 2227, 10.1161/01.ATV.0000147534.69062.dc Cartwright, 2007, Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo, Am J Respir Crit Care Med, 175, 595, 10.1164/rccm.200608-1103OC Hsieh, 2011, Andrographolide enhances nuclear factor-kappaB subunit p65 Ser536 dephosphorylation through activation of protein phosphatase 2A in vascular smooth muscle cells, J Biol Chem, 286, 5942, 10.1074/jbc.M110.123968 Baeuerle, 1997, NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules, Adv Immunol, 65, 111, 10.1016/S0065-2776(08)60742-7 Ishii, 2012, Anti-atherosclerotic potential of dihydropyridine calcium channel blockers, J Atheroscler Thromb, 19, 693, 10.5551/jat.12450 Hernández, 2003, Calcium antagonists and atherosclerosis protection in hypertension, Am J Ther, 10, 409, 10.1097/00045391-200311000-00006 Nakano, 2008, Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice, Atherosclerosis, 196, 172, 10.1016/j.atherosclerosis.2007.03.036 Ram, 2006, Hypertension, possible vascular protection and lercanidipine, Expert Rev Cardiovasc Ther, 4, 783, 10.1586/14779072.4.6.783 Taddei, 2003, Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension, Hypertension, 41, 950, 10.1161/01.HYP.0000063361.70525.3C Liou, 2005, The vasorelaxing action of labedipinedilol-A involves endothelial cell-derived NO and eNOS expression caused by calcium influx, J Cardiovasc Pharmacol, 45, 232, 10.1097/01.fjc.0000154375.88283.5c Wu, 2009, Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling, Pharmacol Res, 59, 48, 10.1016/j.phrs.2008.09.015 Liou, 2004, Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway, J Cardiovasc Pharmacol, 44, 539, 10.1097/00005344-200411000-00005 Hsu, 2011, Labedipinedilol-A prevents lysophosphatidylcholine-induced vascular smooth muscle cell death through reducing reactive oxygen species production and anti-apoptosis, Atherosclerosis, 217, 379, 10.1016/j.atherosclerosis.2011.04.022 Jeon, 2012, Biomarkers and location of atherosclerosis: matrix metalloproteinase-2 may be related to intracranial atherosclerosis, Atherosclerosis, 223, 442, 10.1016/j.atherosclerosis.2012.04.013 Kaneko, 2011, Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization, Atherosclerosis, 217, 350, 10.1016/j.atherosclerosis.2011.03.042 Kalinina, 2004, Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines, Arterioscler Thromb Vasc Biol, 24, 2320, 10.1161/01.ATV.0000145573.36113.8a Inoue, 2007, HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques, Cardiovasc Pathol, 16, 136, 10.1016/j.carpath.2006.11.006 Andersson, 2000, High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes, J Exp Med, 192, 565, 10.1084/jem.192.4.565 Tsoyi, 2011, Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice, Br J Pharmacol, 162, 1498, 10.1111/j.1476-5381.2010.01126.x Jaulmes, 2006, Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta, FASEB J, 20, 1727, 10.1096/fj.05-5514fje Chen, 2004, Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms, J Leukoc Biol, 76, 994, 10.1189/jlb.0404242 Jiang, 2006, The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic–polycytidylic acid or lipopolysaccharide, J Immunol, 177, 3337, 10.4049/jimmunol.177.5.3337 Kranzhöfer, 1999, Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein, Arterioscler Thromb Vasc Biol, 19, 255, 10.1161/01.ATV.19.2.255 Rouis, 1999, Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice, Circulation, 100, 533, 10.1161/01.CIR.100.5.533 Hattori, 2004, NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO, Cardiovasc Res, 63, 31, 10.1016/j.cardiores.2004.03.014 Gómez-Hernández, 2006, Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB, Atherosclerosis, 187, 139, 10.1016/j.atherosclerosis.2005.08.035 Vermeulen, 2003, Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1), EMBO J, 22, 1313, 10.1093/emboj/cdg139 Penzo, 2010, Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis, J Immunol, 184, 4497, 10.4049/jimmunol.0903131 Hattori, 2003, Lipopolysaccharide activates Akt in vascular smooth muscle cells resulting in induction of inducible nitric oxide synthase through nuclear factor-kappa B activation, Eur J Pharmacol, 481, 153, 10.1016/j.ejphar.2003.09.034 Ishii, 2010, Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice, Arterioscler Thromb Vasc Biol, 30, 1598, 10.1161/ATVBAHA.109.202309 Severa, 2005, Inhibition of interleukin-12 expression in diltiazem-treated dendritic cells through the reduction of nuclear factor-kappa B transcriptional activity, Biochem Pharmacol, 69, 425, 10.1016/j.bcp.2004.10.004 Cuschieri, 2002, Slow channel calcium inhibition blocks proinflammatory gene signaling and reduces macrophage responsiveness, J Trauma, 52, 434